{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:20:20Z","timestamp":1793762420385,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Leipzig"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>There are complex associations between the imaging phenotype and underlying histopathology of hepatocellular carcinomas (HCC). The recently proposed SMARS score (acronym comprising <jats:italic>S<\/jats:italic>hape of tumour, <jats:italic>M<\/jats:italic>osaic architecture, <jats:italic>A<\/jats:italic>FP level, <jats:italic>R<\/jats:italic>im APHE, and <jats:italic>S<\/jats:italic>atellite lesion) could discriminate proliferative and non-proliferative HCC tumours in a non-invasive way and was associated with treatment outcomes. However, a systematic validation of this score is needed and it is unclear whether associations with histopathology features exist. The present study elucidates possible correlations between the SMARS score defined by CT and MRI images with immunohistochemistry features of the pathological specimens in a curatively treated HCC cohort. A total of 44 patients (mean age: 59.6\u2009\u00b1\u200910.7 years) with histologically confirmed HCC, who underwent curative surgical resection, were included in the present analysis. Contrast enhanced MRI and CT images were performed before surgery and the SMARS score was calculated. The pathological specimens were analyzed for programmed death ligand 1 (PD-L1), Glypican-3, CD3-tumour infiltrating lymphocyte, CD68 positive cells, CD34 positive microvessel density (MVD). The median SMARS score derived from MRI images was 1.4 (interquartile range: -0.32; 2.18) and from CT images it was \u2212\u20090.32 (interquartile range: -1.08; 0.56). According to the proposed threshold, 29 tumours were categorized as proliferative HCC (82.9%) and six tumours as nonproliferative HCC (17.1%) accordingly to the MRI SMARS score. According to the CT SMARS score 24 tumours were categorized as proliferative HCC (61.5%) and 15 as nonproliferative HCC (38.5%). The SMARS score derived from MRI images showed no correlations with the PD-L1, CD68, CD3 and MVD parameters. However, a moderate association was shown between the SMARS score with the Glypican-3 expression (<jats:italic>r<\/jats:italic>\u2009=\u20090.37, <jats:italic>p<\/jats:italic>\u2009=\u20090.03). The SMARS score derived from CT images, instead, showed correlations with two of the PD-L1 parameters (for PD-L1 tumour positive score <jats:italic>r<\/jats:italic>=-0.37, <jats:italic>p<\/jats:italic>\u2009=\u20090.02 and for PD-L1 combined positive score <jats:italic>r<\/jats:italic>=-0.35, <jats:italic>p<\/jats:italic>\u2009=\u20090.03) while no other association with the remaining parameters was detected.\u00a0The SMARS score as a promising novel imaging score is associated with the Glypican-3  and PD-L1 expression in curatively treated HCC patients. Differences between the CT and MRI defined score needs to be investigated in further trials on larger patient cohorts.<\/jats:p>","DOI":"10.1038\/s41598-025-09918-8","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T10:10:23Z","timestamp":1752142223000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Associations between the SMARS score derived from CT and MRI with histopathological features in HCC"],"prefix":"10.1038","volume":"15","author":[{"given":"Daniele","family":"Romeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Kathrin","family":"H\u00f6hn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Michael","family":"Tautenhahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Seehofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Scheuermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timm","family":"Denecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Jonas","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"9918_CR1","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3748\/wjg.15.1289","volume":"15","author":"B Ariff","year":"2009","unstructured":"Ariff, B. et al. Imaging of liver cancer. World J. Gastroenterol. 15, 1289\u20131300 (2009).","journal-title":"World J. Gastroenterol."},{"key":"9918_CR2","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","volume":"362","author":"JM Llovet","year":"2003","unstructured":"Llovet, J. M., Burroughs, A. & Bruix, J. Hepatocellular carcinoma. Lancet 362, 1907\u20131917 (2003).","journal-title":"Lancet"},{"issue":"4","key":"9918_CR3","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1007\/s00330-024-10606-w","volume":"34","author":"R Cannella","year":"2024","unstructured":"Cannella, R., Zins, M. & Brancatelli, G. ESR essentials: diagnosis of hepatocellular carcinoma-practice recommendations by ESGAR. Eur. Radiol. 34 (4), 2127\u20132139 (2024).","journal-title":"Eur. Radiol."},{"issue":"2","key":"9918_CR4","doi-asserted-by":"publisher","first-page":"e230457","DOI":"10.1148\/radiol.230457","volume":"308","author":"Y Bao","year":"2023","unstructured":"Bao, Y. et al. Identifying proliferative hepatocellular carcinoma at pretreatment CT: implications for therapeutic outcomes after transarterial chemoembolization. Radiology 308 (2), e230457 (2023).","journal-title":"Radiology"},{"issue":"1","key":"9918_CR5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13244-024-01792-8","volume":"15","author":"P Zhou","year":"2024","unstructured":"Zhou, P. et al. Identification of proliferative hepatocellular carcinoma using the SMARS score and implications for microwave ablation. Insights Imaging. 15 (1), 220 (2024).","journal-title":"Insights Imaging"},{"issue":"1","key":"9918_CR6","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/s12885-019-5574-8","volume":"19","author":"K Huang","year":"2019","unstructured":"Huang, K. et al. Imaging biomarkers for well and moderate hepatocellular carcinoma: preoperative magnetic resonance image and histopathological correlation. BMC Cancer. 19 (1), 364 (2019).","journal-title":"BMC Cancer"},{"issue":"11","key":"9918_CR7","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1007\/s00261-021-03240-3","volume":"46","author":"FC Piskin","year":"2021","unstructured":"Piskin, F. C., Balli, H. T., Erdo\u011fan, K. E., Sozutok, S. & Aikimbaev, K. Whole tumor volumetric ADC analysis: relationships with histopathological differentiation of hepatocellular carcinoma. Abdom. Radiol. (NY). 46 (11), 5180\u20135189 (2021).","journal-title":"Abdom. Radiol. (NY)"},{"issue":"2","key":"9918_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2214\/AJR.10.5439","volume":"197","author":"JY Choi","year":"2011","unstructured":"Choi, J. Y. et al. Gadoxetate disodium-enhanced hepatobiliary phase MRI of hepatocellular carcinoma: correlation with histological characteristics. AJR Am. J. Roentgenol. 197 (2), 399\u2013405 (2011).","journal-title":"AJR Am. J. Roentgenol."},{"issue":"7","key":"9918_CR9","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1007\/s00330-020-06675-2","volume":"30","author":"SJ Hectors","year":"2020","unstructured":"Hectors, S. J. et al. MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. Eur. Radiol. 30 (7), 3759\u20133769 (2020).","journal-title":"Eur. Radiol."},{"issue":"1","key":"9918_CR10","doi-asserted-by":"publisher","first-page":"e222801","DOI":"10.1148\/radiol.222801","volume":"307","author":"V Chernyak","year":"2023","unstructured":"Chernyak, V. et al. LI-RADS: looking back, looking forward. Radiology 307 (1), e222801 (2023).","journal-title":"Radiology"},{"issue":"1","key":"9918_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00261-017-1228-y","volume":"43","author":"V Chernyak","year":"2018","unstructured":"Chernyak, V., Santillan, C. S., Papadatos, D. & Sirlin, C. B. LI-RADS\u00ae algorithm: CT and MRI. Abdom. Radiol. (NY). 43 (1), 111\u2013126 (2018).","journal-title":"Abdom. Radiol. (NY)"},{"issue":"10","key":"9918_CR12","doi-asserted-by":"publisher","first-page":"6902","DOI":"10.1007\/s00330-023-09669-y","volume":"33","author":"TA Auer","year":"2023","unstructured":"Auer, T. A. et al. Gd-EOB MRI for HCC subtype differentiation in a Western population according to the 5th edition of the world health organization classification. Eur. Radiol. 33 (10), 6902\u20136915 (2023).","journal-title":"Eur. Radiol."},{"issue":"1","key":"9918_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000511384","volume":"10","author":"A Surov","year":"2021","unstructured":"Surov, A. et al. Diffusion-Weighted imaging reflects tumor grading and microvascular invasion in hepatocellular carcinoma. Liver Cancer. 10 (1), 10\u201324 (2021).","journal-title":"Liver Cancer"},{"issue":"4","key":"9918_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/02841850510021247","volume":"46","author":"B Wang","year":"2005","unstructured":"Wang, B., Gao, Z. Q. & Yan, X. Correlative study of angiogenesis and dynamic contrast-enhanced magnetic resonance imaging features of hepatocellular carcinoma. Acta Radiol. 46 (4), 353\u2013358 (2005).","journal-title":"Acta Radiol."},{"issue":"4","key":"9918_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.21037\/atm.2020.01.04","volume":"8","author":"Z Ye","year":"2020","unstructured":"Ye, Z. et al. Preoperative prediction of hepatocellular carcinoma with highly aggressive characteristics using quantitative parameters derived from hepatobiliary phase MR images. Ann. Transl Med. 8 (4), 85 (2020).","journal-title":"Ann. Transl Med."},{"key":"9918_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.clinimag.2020.11.057","volume":"76","author":"L Song","year":"2021","unstructured":"Song, L., Li, J. & Luo, Y. The importance of a nonsmooth tumor margin and incomplete tumor capsule in predicting HCC microvascular invasion on preoperative imaging examination: a systematic review and meta-analysis. Clin. Imaging. 76, 77\u201382 (2021).","journal-title":"Clin. Imaging"},{"key":"9918_CR17","doi-asserted-by":"crossref","unstructured":"Zhou, F. et al. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. ;38(2):741\u2013767;, Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2015;14(4):361-6 (2018).","DOI":"10.1002\/med.21455"},{"issue":"1","key":"9918_CR18","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s40001-024-02073-2","volume":"29","author":"AR Devan","year":"2024","unstructured":"Devan, A. R. et al. The role of glypican-3 in hepatocellular carcinoma: insights into diagnosis and therapeutic potential. Eur. J. Med. Res. 29 (1), 490 (2024).","journal-title":"Eur. J. Med. Res."},{"key":"9918_CR19","doi-asserted-by":"publisher","first-page":"973153","DOI":"10.3389\/fimmu.2022.973153","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. Preoperative prediction of glypican-3 positive expression in solitary hepatocellular carcinoma on gadoxetate-disodium enhanced magnetic resonance imaging. Front. Immunol. 13, 973153 (2022).","journal-title":"Front. Immunol."},{"key":"9918_CR20","doi-asserted-by":"publisher","first-page":"1142916","DOI":"10.3389\/fonc.2023.1142916","volume":"13","author":"P Liu","year":"2023","unstructured":"Liu, P. et al. Multiparametric MRI combined with clinical factors to predict glypican-3 expression of hepatocellular carcinoma. Front. Oncol. 13, 1142916 (2023).","journal-title":"Front. Oncol."},{"issue":"1","key":"9918_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40364-023-00535-z","volume":"12","author":"N Zhang","year":"2024","unstructured":"Zhang, N. et al. Biomarkers and prognostic factors of PD-1\/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma. Biomark. Res. 12 (1), 26 (2024).","journal-title":"Biomark. Res."},{"issue":"6","key":"9918_CR22","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2217\/bmm-2021-1051","volume":"16","author":"Y Qian","year":"2022","unstructured":"Qian, Y. et al. Prognostic value of PD-L1 expression combined with hypoxia-associated immunosuppression in hepatocellular carcinoma. Biomark. Med. 16 (6), 435\u2013448 (2022).","journal-title":"Biomark. Med."},{"key":"9918_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12935-019-0738-9","volume":"19","author":"GM Liu","year":"2019","unstructured":"Liu, G. M., Li, X. G. & Zhang, Y. M. Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis. Cancer Cell. Int. 19, 22 (2019).","journal-title":"Cancer Cell. Int."},{"issue":"1","key":"9918_CR24","doi-asserted-by":"publisher","first-page":"7710","DOI":"10.1038\/s41598-023-34763-y","volume":"13","author":"XQ Gong","year":"2023","unstructured":"Gong, X. Q. et al. Radiomics models based on multisequence MRI for predicting PD-1\/PD-L1 expression in hepatocellular carcinoma. Sci. Rep. 13 (1), 7710 (2023).","journal-title":"Sci. Rep."},{"issue":"10","key":"9918_CR25","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.3390\/diagnostics11101875","volume":"11","author":"Y Tian","year":"2021","unstructured":"Tian, Y. et al. Assessing PD-L1 expression level via preoperative MRI in HCC based on integrating deep learning and radiomics features. Diagnostics (Basel). 11 (10), 1875 (2021).","journal-title":"Diagnostics (Basel)"},{"issue":"14","key":"9918_CR26","doi-asserted-by":"publisher","first-page":"11471","DOI":"10.3390\/ijms241411471","volume":"24","author":"M Kotsari","year":"2023","unstructured":"Kotsari, M., Dimopoulou, V., Koskinas, J. & Armakolas, A. Immune system and hepatocellular carcinoma (HCC): new insights into HCC progression. Int. J. Mol. Sci. 24 (14), 11471. https:\/\/doi.org\/10.3390\/ijms241411471 (2023). PMID: 37511228; PMCID: PMC10380581.","journal-title":"Int. J. Mol. Sci."},{"key":"9918_CR27","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.2147\/JHC.S381764","volume":"9","author":"H Feng","year":"2022","unstructured":"Feng, H. et al. Tumor microenvironment in hepatocellular carcinoma: key players for immunotherapy. J. Hepatocell Carcinoma. 9, 1109\u20131125 (2022). PMID: 36320666; PMCID: PMC9618253.","journal-title":"J. Hepatocell Carcinoma"},{"issue":"1","key":"9918_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","volume":"18","author":"R Baghban","year":"2020","unstructured":"Baghban, R. et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell. Commun. Signal. 18 (1), 59. https:\/\/doi.org\/10.1186\/s12964-020-0530-4 (2020). PMID: 32264958; PMCID: PMC7140346.","journal-title":"Cell. Commun. Signal."},{"key":"9918_CR29","doi-asserted-by":"publisher","unstructured":"Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature. ;541(7637):321\u2013330. (2017). https:\/\/doi.org\/10.1038\/nature21349. PMID: 28102259.","DOI":"10.1038\/nature21349"},{"issue":"11","key":"9918_CR30","doi-asserted-by":"publisher","first-page":"104181","DOI":"10.1016\/j.drudis.2024.104181","volume":"29","author":"L Hu","year":"2024","unstructured":"Hu, L., Sun, C., Yuan, K. & Yang, P. Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment. Drug Discov Today. 29 (11), 104181. https:\/\/doi.org\/10.1016\/j.drudis.2024.104181 (2024). Epub 2024 Sep 13. PMID: 39278561.","journal-title":"Drug Discov Today"},{"key":"9918_CR31","doi-asserted-by":"publisher","first-page":"1103521","DOI":"10.3389\/fonc.2023.1103521","volume":"13","author":"T Xie","year":"2023","unstructured":"Xie, T. et al. Self-supervised contrastive learning using CT images for PD-1\/PD-L1 expression prediction in hepatocellular carcinoma. Front. Oncol. 13, 1103521. https:\/\/doi.org\/10.3389\/fonc.2023.1103521 (2023). PMID: 36937385; PMCID: PMC10020705.","journal-title":"Front. Oncol."},{"key":"9918_CR32","doi-asserted-by":"publisher","first-page":"101597","DOI":"10.1016\/j.tranon.2022.101597","volume":"27","author":"HF Liu","year":"2023","unstructured":"Liu, H. F., Zhang, Y. Z., Wang, Q., Zhu, Z. H. & Xing, W. A nomogram model integrating LI-RADS features and radiomics based on contrast-enhanced magnetic resonance imaging for predicting microvascular invasion in hepatocellular carcinoma falling the Milan criteria. Transl Oncol. 27, 101597. https:\/\/doi.org\/10.1016\/j.tranon.2022.101597 (2023). Epub 2022 Dec 8. PMID: 36502701; PMCID: PMC9758568.","journal-title":"Transl Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09918-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09918-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09918-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T04:26:04Z","timestamp":1757219164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09918-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9918"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-09918-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the local ethics committees (University of Leipzig) and conducted in accordance with the International Conference on Harmonization, Good Clinical Practice guidelines, and the Declaration of Helsinki. All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"24862"}}